Study Links GLP-1 Drugs to 30% Lower Breast Cancer Risk in 111,000 Women
Updated
Updated · abcnews.com · Jun 3
Study Links GLP-1 Drugs to 30% Lower Breast Cancer Risk in 111,000 Women
2 articles · Updated · abcnews.com · Jun 3
Summary
A JCO Oncology Practice study of more than 111,000 overweight or obese women ages 45 to 80 found GLP-1 users had about a 30% lower risk of developing breast cancer.
Researchers and ABC News medical correspondent Dr. Tara Narula said the drugs could help by reducing weight, inflammation and insulin resistance—factors tied to higher postmenopausal breast cancer risk.
Narula also cited early evidence that GLP-1s may directly slow tumor growth and metastatic progression, though the study's lead author said the findings are observational and do not prove causation.
Breast cancer accounts for 1 in 3 new female cancer diagnoses in the U.S., and screening guidance still calls for average-risk women ages 40 to 74 to get mammograms every two years.
GLP-1s show promise against cancer, but what are the unknown long-term health risks of using these powerful drugs for years?
With new oral GLP-1s now approved, could a daily pill become the future of breast cancer prevention?
Weight-loss drugs may cut breast cancer risk, but can new government programs solve the extreme cost barrier for patients?
Major Study Finds GLP-1s Associated with Reduced Breast Cancer Incidence: Implications for Prevention
Overview
A major retrospective study presented at ASCO 2026 revealed a strong association between GLP-1 medication use and reduced breast cancer risk, sparking excitement in the medical community. This finding is significant because GLP-1s, originally used for diabetes and weight management, may also offer protective benefits against breast cancer by influencing biological pathways linked to cancer development. However, the study was observational, so it cannot prove a direct cause-and-effect relationship. Important factors like specific GLP-1 agents, treatment duration, and genetic risk were not evaluated, and unmeasured variables could still affect the results. More research is needed to confirm these promising findings.